17.09.2015 12:35:07
|
Achillion Reports Positive Interim Results From Odalasvir Study - Quick Facts
(RTTNews) - Achillion Pharmaceuticals, Inc. (ACHN) announced additional interim results from a Phase 2 study evaluating odalasvir, also known as ACH-3102, a NS5A inhibitor, in combination with sofosbuvir, without ribavirin, for either six or eight weeks of treatment in patients with treatment-naïve genotype 1 chronic hepatitis C virus infection. The primary objective of the study was determination of sustained viral response 12 weeks, or SVR12, after the completion of therapy. The company said, of the patients treated for six weeks in this cross-over cohort, 100 percent remained HCV RNA undetectable twelve weeks after completing therapy.
The company said Odalasvir and sofosbuvir were well tolerated in the Phase 2, open-label, randomized, partial-crossover study with no significant adverse events, ECG findings, or lab abnormalities observed during treatment.
In May 2015, Achillion announced it had granted Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, an exclusive, worldwide license to develop and, upon regulatory approval, commercialize HCV products and regimens containing one or more of Achillion's HCV assets which include odalasvir, ACH-3422, and sovaprevir.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Johnson & Johnsonmehr Nachrichten
17.03.25 |
Gute Stimmung in New York: Dow Jones zeigt sich am Montagnachmittag fester (finanzen.at) | |
14.03.25 |
Freundlicher Handel: Dow Jones zum Start des Freitagshandels auf grünem Terrain (finanzen.at) | |
12.03.25 |
Börse New York: Dow Jones in der Gewinnzone (finanzen.at) | |
12.03.25 |
Angespannte Stimmung in New York: Dow Jones sackt mittags ab (finanzen.at) | |
12.03.25 |
Dow Jones 30 Industrial-Papier Johnson Johnson-Aktie: So viel Gewinn hätte ein Johnson Johnson-Investment von vor einem Jahr eingefahren (finanzen.at) | |
05.03.25 |
Zuversicht in New York: Dow Jones letztendlich mit Kursplus (finanzen.at) | |
05.03.25 |
Zuversicht in New York: Dow Jones am Nachmittag freundlich (finanzen.at) | |
05.03.25 |
Dow Jones 30 Industrial-Titel Johnson Johnson-Aktie: So viel Gewinn hätte ein Investment in Johnson Johnson von vor 10 Jahren eingebracht (finanzen.at) |
Analysen zu Achillion Pharmaceuticals IncShsmehr Analysen
Aktien in diesem Artikel
Johnson & Johnson | 148,78 | -0,09% |
|